FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2544552649> ?p ?o ?g. }

• W2544552649 endingPage "1593" @default.
• W2544552649 startingPage "1583" @default.
• W2544552649 abstract "Background: Approximately 50% of newly diagnosed cancer patients start taking dietary supplements. Men’s health supplements (MHSs), which we define as supplements that are specifically marketed with the terms men’s health and prostate health (or similar permutations), are often mislabeled as having potential anticancer benefits. Objective: We evaluated the effects of MHSs on patient outcomes and toxicities in patients who were undergoing definitive intensity-modulated radiation therapy (IMRT) for localized prostate cancer. Design: This retrospective analysis included patients who were being treated at a National Cancer Institute–designated comprehensive cancer center and consented to have information stored in a prospective database. MHSs were queried online. Outcome measures were freedom from biochemical failure (FFBF) (biochemical failure was defined with the use of the prostate-specific antigen nadir + 2-ng/mL definition), freedom from distant metastasis (FFDM), cancer-specific survival (CSS), and overall survival (OS) as well as toxicities. Kaplan-Meier analysis, log-rank tests, Fine and Gray competing-risk regression (to adjust for patient and lifestyle factors), and Cox models were used. Results: From 2001 to 2012, 2207 patients were treated with IMRT with a median dose of 78 Gy, and a median follow-up of 46 mo. Of these patients, 43% were low risk, 37% were intermediate risk, and 20% were high risk; 10% used MHSs. MHSs contained a median of 3 identifiable ingredients (range: 0–78 ingredients). Patients who were taking an MHS compared with those who were not had improved 5-y OS (97% compared with 92%, respectively; P = 0.01), but there were no differences in the FFBF (94% compared with 89%, respectively; P = 0.12), FFDM (96% compared with 97%, respectively; P = 0.32), or CSS (100% compared with 99%, respectively; P = 0.22). The unadjusted association between MHS use and improved OS was attenuated after adjustment for patient lifestyle factors and comorbidities. There was no difference in toxicities between the 2 groups (late-grade 3–4 genitourinary <3%; gastrointestinal <4%). Conclusion: The use of MHSs is not associated with outcomes or toxicities." @default.
• W2544552649 created "2016-11-04" @default.
• W2544552649 creator A5011633254 @default.
• W2544552649 creator A5030000060 @default.
• W2544552649 creator A5030553105 @default.
• W2544552649 creator A5030829907 @default.
• W2544552649 creator A5049646055 @default.
• W2544552649 creator A5057775605 @default.
• W2544552649 creator A5061194777 @default.
• W2544552649 creator A5080057051 @default.
• W2544552649 creator A5085787232 @default.
• W2544552649 date "2016-12-01" @default.
• W2544552649 modified "2023-09-29" @default.
• W2544552649 title "Men’s health supplement use and outcomes in men receiving definitive intensity-modulated radiation therapy for localized prostate cancer" @default.
• W2544552649 cites W1525444530 @default.
• W2544552649 cites W1552792839 @default.
• W2544552649 cites W1582872071 @default.
• W2544552649 cites W1847301111 @default.
• W2544552649 cites W1869362176 @default.
• W2544552649 cites W1915284206 @default.
• W2544552649 cites W1931827816 @default.
• W2544552649 cites W1947343385 @default.
• W2544552649 cites W1981890034 @default.
• W2544552649 cites W1986748287 @default.
• W2544552649 cites W2002384741 @default.
• W2544552649 cites W2011957420 @default.
• W2544552649 cites W2023397502 @default.
• W2544552649 cites W2038981426 @default.
• W2544552649 cites W2046890382 @default.
• W2544552649 cites W2061988762 @default.
• W2544552649 cites W2062117336 @default.
• W2544552649 cites W2062531786 @default.
• W2544552649 cites W2071523757 @default.
• W2544552649 cites W2073229943 @default.
• W2544552649 cites W2073988927 @default.
• W2544552649 cites W2088149771 @default.
• W2544552649 cites W2094156804 @default.
• W2544552649 cites W2109625042 @default.
• W2544552649 cites W2116315220 @default.
• W2544552649 cites W2125345210 @default.
• W2544552649 cites W2129528814 @default.
• W2544552649 cites W2133443143 @default.
• W2544552649 cites W2140068099 @default.
• W2544552649 cites W2141944007 @default.
• W2544552649 cites W2148587874 @default.
• W2544552649 cites W2156776019 @default.
• W2544552649 cites W2158827225 @default.
• W2544552649 cites W2161156680 @default.
• W2544552649 cites W2161817637 @default.
• W2544552649 cites W2166975295 @default.
• W2544552649 cites W2168613688 @default.
• W2544552649 cites W2313148216 @default.
• W2544552649 cites W2315090735 @default.
• W2544552649 cites W2420319362 @default.
• W2544552649 cites W2443061927 @default.
• W2544552649 cites W2592461925 @default.
• W2544552649 cites W4245684785 @default.
• W2544552649 cites W4295115868 @default.
• W2544552649 doi "https://doi.org/10.3945/ajcn.115.119958" @default.
• W2544552649 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5118729" @default.
• W2544552649 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27797706" @default.
• W2544552649 hasPublicationYear "2016" @default.
• W2544552649 type Work @default.
• W2544552649 sameAs 2544552649 @default.
• W2544552649 citedByCount "2" @default.
• W2544552649 countsByYear W25445526492021 @default.
• W2544552649 countsByYear W25445526492023 @default.
• W2544552649 crossrefType "journal-article" @default.
• W2544552649 hasAuthorship W2544552649A5011633254 @default.
• W2544552649 hasAuthorship W2544552649A5030000060 @default.
• W2544552649 hasAuthorship W2544552649A5030553105 @default.
• W2544552649 hasAuthorship W2544552649A5030829907 @default.
• W2544552649 hasAuthorship W2544552649A5049646055 @default.
• W2544552649 hasAuthorship W2544552649A5057775605 @default.
• W2544552649 hasAuthorship W2544552649A5061194777 @default.
• W2544552649 hasAuthorship W2544552649A5080057051 @default.
• W2544552649 hasAuthorship W2544552649A5085787232 @default.
• W2544552649 hasBestOaLocation W25445526491 @default.
• W2544552649 hasConcept C121608353 @default.
• W2544552649 hasConcept C126322002 @default.
• W2544552649 hasConcept C143998085 @default.
• W2544552649 hasConcept C188816634 @default.
• W2544552649 hasConcept C2780192828 @default.
• W2544552649 hasConcept C50382708 @default.
• W2544552649 hasConcept C509974204 @default.
• W2544552649 hasConcept C71924100 @default.
• W2544552649 hasConceptScore W2544552649C121608353 @default.
• W2544552649 hasConceptScore W2544552649C126322002 @default.
• W2544552649 hasConceptScore W2544552649C143998085 @default.
• W2544552649 hasConceptScore W2544552649C188816634 @default.
• W2544552649 hasConceptScore W2544552649C2780192828 @default.
• W2544552649 hasConceptScore W2544552649C50382708 @default.
• W2544552649 hasConceptScore W2544552649C509974204 @default.
• W2544552649 hasConceptScore W2544552649C71924100 @default.
• W2544552649 hasFunder F4320309603 @default.
• W2544552649 hasFunder F4320332161 @default.
• W2544552649 hasFunder F4320337351 @default.
• W2544552649 hasIssue "6" @default.

• next